z-logo
open-access-imgOpen Access
Need for Treatment of Gonorrhea to be Effective againstChlamydia trachomatis
Author(s) -
William Bowie,
Joanne Ast,
Linda Sibau,
Carol E. Shaw,
HUGH D. JONES,
W. A. P. Black
Publication year - 1992
Publication title -
canadian journal of infectious diseases and medical microbiology
Language(s) - English
Resource type - Journals
eISSN - 1918-1493
pISSN - 1712-9532
DOI - 10.1155/1993/613963
Subject(s) - gonorrhea , neisseria gonorrhoeae , chlamydia trachomatis , ceftriaxone , tetracycline , medicine , microbiology and biotechnology , antibiotics , gastroenterology , gynecology , biology , immunology , human immunodeficiency virus (hiv)
Men and women with gonorrhea or contact to gonorrhea are frequently co-infected with Chlamydia trachomatis. To assess the importance of using treatment regimens active against both Neisseria gonorrhoeae and C trachomatis, tetracycline 500 mg orally four times daily for five days, with activity against both organisms, was compared with ceftriaxone, 250 mg once intramuscularly, with activity against only N gonorrhoeae. N gonorrhoeae microbiological failure occurred in six of 148 patients (4%) on tetracycline and zero of 85 on ceftriaxone. Microbiological failure for C trachomatis occurred in zero of 27 on tetracycline and 10 of 12 (83%) on ceftriaxone (P<0.001). In addition, 14 others on ceftriaxone had C trachomatis first isolated after treatment. When all types of microbiologialc and clinical failures are included, outcome was significantly better on tetracycline (P<0.001). Optimal treatment of patients with gonorrhea must include regimens with activity against both C trachomatis and N gonorrhoeae.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom